In particular, during treatment of ccRCC patients with PD-L1 inhibitors, dynamic changes in CTCs’ PD-L1 expression may have prognostic value, and CTC counts may play a role in treatment monitoring [101]. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.